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ABSTRACT
Osteosarcoma is an aggressive bone cancer that has a high propensity for 
metastasis to the lungs. Patients with metastatic disease face a very poor prognosis. 
Therefore, novel therapeutics, efficiently suppressing the metastatic process, are 
urgently needed. Integrins play a pivotal role in tumor cell adhesion, motility and 
metastasis. Here, we evaluated αvβ3 and αvβ5 integrin inhibition with cilengitide 
as a novel metastasis-suppressive therapeutic approach in osteosarcoma. 
Immunohistochemical analysis of αvβ3 and αvβ5 integrins expression in a tissue 
microarray of tumor specimens collected from osteosarcoma patients revealed 
that αvβ5 integrin is mainly found on tumor cells, whereas αvβ3 is predominantly 
expressed by stromal cells. In vitro functional assays demonstrated that cilengitide 
dose-dependently inhibited de novo adhesion, provoked detachment and inhibited 
migration of osteosarcoma cell lines. Cilengitide induced a decline in cell viability, 
blocked the cell cycle in the G1 phase and caused anoikis by activation of the Hippo 
pathway. In a xenograft orthotopic mouse model cilengitide minimally affected 
intratibial primary tumor growth but, importantly, suppressed pulmonary metastasis. 
The data demonstrate that targeting αvβ3 and αvβ5 integrins in osteosarcoma should 
be considered as a novel therapeutic option for patients with metastatic disease.
INTRODUCTION
Osteosarcoma, a highly aggressive bone cancer 
mainly affecting children and young adults, frequently 
metastasizes to the lungs [1]. Metastases are detectable in 
20% of the patients at the time of diagnosis and 80% of the 
patients initially presenting with localized disease develop 
metastases later on [2]. Patients with metastases have a 
long-term survival rate of only 20% despite multiple 
efforts to improve treatment efficacies [3]. Therefore, the 
development of innovative therapeutic strategies targeting 
metastasis, the major cause of death of osteosarcoma 
patients, is urgently needed to improve the prognosis of 
these patients.
Integrins, a family of heterodimeric cell surface 
receptors consisting of α and β subunits, are well-known 
adhesion molecules expressed in both tumor cells and 
tumor-associated healthy cells [4]. Through binding to 
various extracellular matrix proteins, integrins affect 
tumor cell attachment, survival, motility, invasion and 
metastasis. Preclinical and clinical research on integrins 
in cancer, particularly on αvβ3 and αvβ5, revealed 
their substantial potential as therapeutic targets for the 
treatment of different cancer types [5, 6]. Cilengitide, a 
cyclic RGD-containing pentapeptide, was recognized as 
a selective inhibitor of αvβ3 and αvβ5 integrin-mediated 
cell-cell and cell-matrix interaction that exhibited strong 
anti-angiogenic, anti-tumor, anti-invasive activity and 
anti-metastatic activity in various animal models of cancer 
[7–13]. Furthermore, cilengitide displayed a favorable 
safety profile and entered clinical trials for treatment of 
multiple cancer types [14, 15].
At present, little is known about the contribution 
of αvβ3 and αvβ5 integrins to osteosarcoma progression 
and metastasis. αvβ3 integrin expression was found to 
correlate with the migratory and chemotactic activity 
of human osteosarcoma cells towards lung tissue 
homogenates as indicators of metastatic potential [16]. 
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Depletion of αv integrins in human SaOS-2 osteosarcoma 
cells through expression of an intracellular antibody 
suppressed MMP-2 expression and the induction of bone 
differentiation markers, implying that αv integrin regulates 
the osteosarcoma cell phenotype [17]. The expression of 
αvβ3 and αvβ5 heterodimers in human osteosarcoma 
tissue has so far not been investigated.
Here, we investigated αvβ3 and αvβ5 integrins 
as putative therapeutic targets in osteosarcoma. We 
demonstrate that both integrins are present in tumor 
specimens collected from osteosarcoma patients and 
in established cell lines. Inhibiting their function with 
cilengitide suppressed adhesive and migratory properties 
of osteosarcoma cells in vitro, decreased the viability 
and lead to activation of the Hippo signaling pathway. 
A preclinical therapy study in a metastasizing intratibial 
osteosarcoma mouse model showed that intraperitoneal 
treatment of the mice with cilengitide diminished 
pulmonary metastasis. Our findings highlight αvβ3 
and αvβ5 integrins as attractive targets for metastasis 
suppressive treatment in osteosarcoma which deserves 
further investigation.
RESULTS
αvβ3 and αvβ5 integrins are expressed in 
tumor tissue of osteosarcoma patients and in 
established osteosarcoma cell lines
The expression of αvβ3 and αvβ5 integrins 
was investigated in tumor specimens collected from 
osteosarcoma patients and arranged in a tissue microarray. 
Representative tissue microarray sections stained with 
antibodies to αvβ3 and αvβ5 integrins are presented in 
Figure 1A and 1B, respectively. Immunostained αvβ3 
and αvβ5 integrins displayed very different distribution 
patterns in individual tissue microarray spots (Figure 1C). 
The results of the immunohistochemical evaluation of 
αvβ3 and αvβ5 staining pattern, intensity and grading 
score are presented for each tissue microarray core in 
Supplementary Table S1. αvβ3 was predominantly found 
in stromal cells of osteosarcoma biopsies, resections, 
metastases and recurrences, whereas αvβ5 integrin was 
predominantly observed on the majority of tumor cells. 
Interestingly, αvβ3 was expressed on the stromal cells 
in 38 out of 64 biopsies, whereas αvβ3 immunostained 
tumor cells were only found in 1 out of the 64 biopsies. In 
contrast, αvβ5 was detected on tumor cells in 51 out of 60 
biopsies. Likewise, a very high percentage of metastases 
and recurrences were positive for both integrins. In both 
tumor and stromal cells the two integrins were mainly 
localized in membrane structures. Stromal cells stained 
with αvβ3 specific antibodies included multinucleated 
giant osteoclast-like cells. αvβ3 and αvβ5 immunostaining 
was not observed in the tumor vasculature. Moreover, 
the expression of αvβ3 and αvβ5 in tumor tissue did not 
correlate with clinico-pathological characteristics or the 
survival of the patients (data not shown).
A parallel analysis of the expression of αvβ3 and 
αvβ5 integrins at the cell surface of osteosarcoma cell 
lines by flow cytometry showed that both heterodimers 
were expressed by all the cell lines examined (Figure 1D). 
However, the mean fluorescence intensities indicated 
that the expression varied among the cell lines. SaOS-2 
cells expressed the lowest amounts of αvβ3, whereas the 
highest amounts of αvβ5 integrin were observed in U2OS 
cells.
In summary, αvβ3 and αvβ5 integrins were found 
expressed in the majority of the human osteosarcoma 
tissue specimens as well as in all osteosarcoma cell lines 
investigated in the present study.
Cilengitide dose-dependently inhibits de novo 
adhesion to vitronectin, causes detachment and 
impairs migration of osteosarcoma cells
Integrins are known to be involved in adhesion and 
migration processes during the metastatic progression 
and vitronectin is an extracellular matrix component 
binding to both αvβ3 and αvβ5 integrins. Cilengitide 
dose-dependently inhibited de novo adhesion of single 
143-B, U2OS and SaOS-2 cells to vitronectin (Figure 2A). 
Moreover, cilengitide also detached 143-B, U2OS and 
SaOS-2 cells in sub-confluent monolayers grown on 
vitronectin already after 2 hours of treatment in a dose 
dependent manner (Figure 2B). Representative images of 
143-B cells adherent to vitronectin in de novo adhesion 
and detachment assays in the absence or presence of 
indicated cilengitide concentrations are shown in Figure 
2C. Interestingly, the data illustrate that approximately 
1000-times higher concentrations of cilengitide are needed 
to detach the here investigated osteosarcoma cell lines 
from vitronectin than to inhibit their de novo adhesion to 
vitronectin. Remarkable differences in de novo adhesion 
of the cell lines to non-coated or vitronectin-coated culture 
dishes in serum-free medium confirmed that vitronectin 
promotes adhesion and that cilengitide interferes 
with this process (Table 1). Detachment experiments 
carried out in serum-containing medium showed that 
cilengitide detached the osteosarcoma cells at comparable 
concentrations from non-coated or vitronectin-coated 
plastic. This indicated that vitronectin of serum origin 
provided sufficient plastic coating in these experiments as 
previously reported [8, 18]. Consequently, all subsequent 
experiments with fully attached cells were performed 
without previous vitronectin coating.
The impact of cilengitide on the migration activity 
of osteosarcoma cell lines was assessed in a wound healing 
assay using confluent cells, which showed that the migration 
rates were dose-dependently reduced by cilengitide. As 
shown in Figure 2D, the migration of 143-B cells treated with 
0.1 or 1 μg/ml of cilengitide was decreased by 22 ± 3.3% or 
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30 ± 3.6%, respectively, compared to that of non-treated cells 
(P < 0.01). Interestingly, cilengitide had a more pronounced 
effect on the migration of U2OS cells. There 0.5 and 1 μg/ml 
cilengitide reduced the migration by 46 ± 3.1% and 62.7 ± 
3.3%, respectively, compared to non-treated controls (Figure 
2E; P < 0.001). Cilengitide-treated cells remained fully 
Figure 1: Expression of αvβ3 and αvβ5 integrins in human osteosarcoma tissue arranged on a tissue microarray and 
in established human osteosarcoma cell lines. A. Overview images of αvβ3 - or B. of αvβ5 immunostaining of 4.5 μm tissue 
microarray sections consisting of primary biopsies, surgical resections, lung and bone metastases and biopsies of recurrent disease derived 
from osteosarcoma patients. C. Immunohistochemical staining of αvβ3 and αvβ5 integrins in a representative TMA spot. Scale bar, 100 
μm. D. αvβ3 and αvβ5 integrin expression in indicated osteosarcoma cell lines was determined by flow cytometry and expressed as mean 
fluorescence intensity (values); green: αvβ3; orange: αvβ5; blue: secondary antibody control; red: non-stained control.
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Figure 2: Cilengitide (CIL) inhibits de novo adhesion and causes detachment of osteosarcoma cells from vitronectin 
and reduces cell migration. A. CIL dose-dependent inhibition of de novo adhesion (15 minutes) of indicated osteosarcoma cell lines. 
B. CIL dose-dependent detachment (2 hours) of indicated pre-attached osteosarcoma cells. C. Representative images of adherent 143-B 
cells in the absence or presence of indicated concentrations (ng/ml) of CIL. Cell nuclei were visualized by crystal violet staining in the de 
novo adhesion assay (left panels) and by DAPI staining in the detachment assay (right panels). Scale bars, 250 μm. D. Effects of cilengitide 
on the migration of 143-B and E. of U2OS-2 cells. F. Representative images of wounds in U2OS cell monolayers examined microscopically 
immediately after wounding and after 24 hours of incubation with CIL at indicated concentrations (μg/ml). Scale bar, 250 μm. Values in A, 
B, D and E are expressed as the mean ± SEM of at least 3 independent experiments; **, P < 0.01; ***, P < 0.001 vs non-treated control.
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attached, but displayed a partial loss of intercellular contacts 
as presented in Figure 2F. It has been previously reported 
that effects of cilengitide depend on the cell confluency [19]. 
Accordingly, in our experiments, the cell confluency and 
the duration of treatment influenced cilengitide efficacy in 
in vitro functional assays. Along these lines, the migration 
of SaOS-2 cells could not be evaluated in this assay, because 
cilengitide treatment of confluent cells for 24 hours resulted 
in considerable detachment of cells (data not shown).
Taken together, the data presented here demonstrate 
that cilengitide inhibits in vitro metastatic properties of the 
osteosarcoma cells investigated.
Cilengitide decreases cell viability and induces 
G1-cell cycle arrest in vitro
The treatment of 143-B cells with increasing 
concentrations of cilengitide for 24 hours had only a 
modest effect on their viability, reflected by a maximal 
decline of only 30% assessed in a WST-1 assay 
(Figure 3A). U2OS and SaOS-2 cells, on the other hand, 
showed a higher sensitivity, which resulted in a loss of 
viability of 70% and 49%, respectively (Figure 3A). 
Extending the treatment period to 72 hours did not lead 
to greater maximal effects of cilengitide (data not shown). 
However, cilengitide incubation provoked striking 
morphological changes and ultimately cell detachment 
(Figure 3B).
We hypothesized that the limited impact of cilengitide 
on cell viability is associated with changes in cell-cycle 
progression. Indeed, a flow cytometric analysis of cell-
cycle progression upon cilengitide treatment indicated a G1 
cell-cycle arrest in all three cell lines investigated (Figure 
3C). The G1-phase arrest in cilengitide-treated cells was 
accompanied by lower cyclin D1 expression than that 
observed in non-treated cells (Supplementary Figure S1).
We subsequently investigated whether cilengitide 
provokes apoptotic cell death in osteosarcoma cell lines 
by Western blot analysis of PARP cleavage. Minimal or no 
PARP cleavage was observed in 143-B and SaOS-2 cells 
(data not shown). In contrast, U2OS cells responded to 24 
hour cilengitide treatment with a dose-dependent increase in 
PARP cleavage (Supplementary Figure S2A). Interestingly, 
the observed PARP cleavage was not inhibited by Z-VAD, 
indicating caspase-independent apoptosis. This finding 
was consistent with no change in viability of cells treated 
with cilengitide in the absence or presence of Z-VAD 
(Supplementary Figure S2B).
Collectively, these data show that cilengitide has a 
moderate impact on cell viability and provokes G1-phase 
cell cycle arrest. Cilengitide exhibited a cytostatic effect 
in the 143-B and SaOS-2 cell lines. In U2OS cells, on 
the other hand, the cilengitide-evoked cell cycle arrest was 
followed by caspase-independent apoptosis.
Targeting of αvβ3 and αvβ5 integrin with 
cilengitide in vitro activates the Hippo pathway
Recently, it has been reported that cell detachment 
activates the tumor suppressor Hippo pathway, leading 
to inhibition of YAP transcriptional co-activator and to 
anoikis [20]. We, therefore, speculated that targeting αvβ3 
and αvβ5 integrins with cilengitide might activate the 
Hippo pathway. This hypothesis was tested by examining 
the expression of well characterized YAP target genes 
in osteosarcoma cell lines treated with cilengitide for 
indicated time periods. In order to exclude an impact of 
cell viability on gene expression, U2OS and SaOS-2 cells 
were treated for only 6 hours, a time period within which 
cilengitide did not have a significant effect on cell viability 
(Supplementary Figure S2C and S2D). Cilengitide indeed 
inhibited dose-dependently the expression of mRNA from 
the three YAP target genes CTGF, CYR61 and ANKRD1 
(Figure 4A, 4B, and 4C, left panels). The downregulation 
of CYR61 was furthermore confirmed at the protein level 
in all cell lines (Figure 4A, 4B, 4C, right panels).
The results indicate that αvβ3 and αvβ5 integrins might 
be upstream regulators of the Hippo signaling pathway.
Cilengitide treatment minimally affects 
intratibial primary tumor growth, but 
suppresses pulmonary metastasis in a xenograft 
osteosarcoma mouse model
In vivo tumor- and metastasis suppressive activity of 
cilengitide was investigated in a well-established 143-B/
Table 1: Effects of cilengitide on cell adhesion
Cell line De novo adhesion 
(serum-free media)
Detachment (serum-
containing media)
De novo adhesion 
(serum-free media)
Detachment (serum-
containing media)
with Vitronectin coating without Vitronectin coating
IC50 (ng/ml)
143-B 5.2 100 n.a.a 200
U2OS 1.7 5600 n.a. 9300
SaOS-2 1.9 3800 n.a. 3800
a n.a.(not applicable); De novo adhesion too low in the absence of vitronectin
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mCherry/LacZ cell line-derived intratibial osteosarcoma 
model in SCID mice that mimics the human metastatic 
disease with osteolytic bone lesions and lung metastases 
(Figure 5A, left panel) [21]. Daily intraperitoneal 
administration of cilengitide (10 mg/kg body weight) or 
vehicle for 20 days was started 8 days after intratibial 
tumor cell inoculation (Figure 5A, right panel). Periodic 
assessment of primary tumor size by caliper measurements 
and by mCherry fluorescent imaging showed only a minor 
inhibitory effect of cilengitide on primary tumor growth 
(Figure 5B and 5C). A significantly (P < 0.01) smaller 
mean primary tumor volume in cilengitide-treated mice 
than in vehicle-treated animals was only observed at the 
end of the therapy on day 27 after tumor cell inoculation. 
Respective mean final tumor volumes assessed by caliper 
measurements amounted to 169 ± 14 mm3 and 219 ± 17 
mm3, respectively. Consistent with these results, mCherry 
fluorescent signals detected in the tumor-bearing legs 
of living animals were significantly (P < 0.01) lower in 
cilengitide-treated mice than in vehicle-treated control 
mice at the end of the therapy (Figure 5C). X-Ray and 
IVIS images, presented in Figure 5D, show osteolysis and 
mCherry fluorescence in proximal tibias of representative 
mice treated with vehicle or cilengitide for 20 days. 
Importantly, cilengitide treatment had a much more 
pronounced inhibitory effect on pulmonary metastasis, 
assessed ex-vivo in X-Gal stained lungs, than on primary 
tumor growth (Figure 5E). The mean number of metastatic 
foci was 2.2 times lower in lungs of cilengitide-treated 
mice than in lungs dissected from vehicle-treated animals 
(Figure 5F, P < 0.05).
Taken together, cilengitide, selectively targeting 
αvβ3 and αvβ5 integrins, has a limited impact on 
primary tumor development in the intratibial xenograft 
osteosarcoma mouse model investigated here. However, 
it significantly inhibited lung metastasis demonstrating 
that αvβ3 and αvβ5 integrin targeting restrains metastatic 
spread of osteosarcoma.
Figure 3: Effects of cilengitide (CIL) on cell viability, morphology and cell cycle progression. A. Viability of indicated 
cell lines assessed in a WST-1 assay after incubation for 24 hours with CIL at indicated concentrations. B. Representative phase-contrast 
micrographs of cells treated with indicated concentrations (μg/ml) of CIL for 24 hours (143-B, U2OS) or 48 hours (SaOS-2) prior to cell 
cycle analysis. Scale bar, 100 μm. C. Cell cycle distribution (% of total cell population) of indicated osteosarcoma cell lines, assessed by 
flow cytometric analysis of propidium iodide-stained cells, after treatment for 24 hours (143-B, U2OS) or for 48 hours (SaOS-2) with CIL 
at indicated concentrations. Values in A and C represent the mean ± SEM of at least 3 independent experiments; *, P < 0.05; **, P < 0.01 
vs untreated control.
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DISCUSSION
Osteosarcoma is the second leading cause of cancer-
associated death in childhood and adolescence due to its 
high potential for metastatic spread [22]. The identification 
of metastasis promoting mechanisms followed by 
the development of new therapeutic compounds that 
efficiently inhibit these mechanisms will finally help to 
reduce the currently high mortality rate of osteosarcoma 
patients with metastatic disease.
The present study shows for the first time that αvβ3 
and αvβ5 integrins are expressed in the majority of tumors 
Figure 4: Cilengitide (CIL) activates the Hippo pathway. The levels of mRNA encoding the YAP target genes CTGF, CYR61 
or ANKRD1 were analyzed by quantitative RT-PCR (left panels) and normalized to those of GAPDH in total RNA extracts of 143-B 
A. U2OS B. or SaOS-2 cells C. left untreated or treated with indicated concentration of CIL for 24, 6 and 6 hours, respectively. mRNA 
levels normalized to those of GAPDH in non-treated control cells were set to 100%. Values are presented as the mean ± SEM of at least 3 
independent experiments; *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs non-treated control. The expression of CYR61 at the protein level 
and of GAPDH as a reference (right panels) was analyzed on Western blots of whole cell extracts of the indicated cell lines treated for 24 
hours with CIL at indicated concentrations. Representative Western blots of three independent experiments.
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Figure 5: Cilengitide (CIL) inhibits pulmonary metastasis in vivo. A. X-Ray image of the site of intratibial injection of 143-
B/mCherry/LacZ cells taken at the time of the tumor cell injection (TCI) on Day 0 (left panel). Protocol for the treatment of tumor 
bearing mice with vehicle (control) or CIL (10 mg/kg body weight) (right panel). B. Primary tumor growth over time monitored by caliper 
measurements of the tumor volume at indicated time points in mice treated with vehicle or with CIL. C. mCherry fluorescence indicating 
primary tumor growth over time in the same vehicle- or CIL-treated animals. D. X-Ray images of tumor bearing legs and IVIS images 
of tumor bearing animals taken at the end of the experiment from representative mice treated with vehicle or with CIL. E. Representative 
pictures and F. quantification of X-gal stained pulmonary metastases (arrows) on lung mounts collected and prepared as described in the 
Materials and Methods from vehicle or CIL treated mice at sacrifice 28 days after TCI. Scale bar, 250 μm. Values in B, C and F are the mean 
± SEM of the data collected in 12 vehicle- and 11 CIL-treated mice; *, P < 0.05; **, P < 0.01.
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of osteosarcoma patients and that selective targeting of 
these integrins needs to be considered as novel metastasis-
suppressive treatment approach in osteosarcoma. 
Interestingly, αvβ5 integrin was found to be predominantly 
expressed by tumor cells whereas αvβ3 integrin was 
mainly recognized on stromal multinucleated osteoclast-
like cells. These intratumoral benign cells have been 
observed in 25% of osteosarcomas [23]. Our findings are 
consistent with those of a report demonstrating that αvβ3 
integrin surface expression is essential to the formation of 
osteoclast-like multinucleated cells [24]. Our observations 
confirm previously reported high expression of all αv 
integrins in tumor specimens collected from twenty 
osteosarcoma patients [25]. The expression pattern of αvβ3 
integrin in osteosarcoma is similar to that described in 
breast and gastric cancer [26, 27]. Furthermore, abundant 
expression of integrins described for brain metastases 
from various primary malignancies is in good agreement 
with our findings [26, 28]. However, unlike several recent 
studies in a variety of human cancers employing the 
integrin antibodies used in our study, we did not observe 
immunoreactivity in tumor vascular structures [28, 29]. As 
integrins investigated here are expressed in both the tumor 
cells and the stromal components of osteosarcoma, their 
targeting with cilengitide might be a particularly effective 
treatment approach since it is simultaneously directed 
towards the tumor cells and the tumor microenvironment.
The here reported results of an in vivo study, carried 
out in an orthotopic xenograft mouse model that closely 
mimics the human disease, demonstrate a predominant 
anti-metastatic activity of cilengitide, implicating that 
αvβ3/αvβ5 integrins play an important role during 
metastasis of osteosarcoma. These results are in line 
with those of the in vitro experiments, demonstrating 
that cilengitide suppressed cellular adhesion and motility, 
important properties of metastasizing cells, in a panel of 
αvβ3/αvβ5 expressing osteosarcoma cell lines much like in 
meningioma [30]. Using clinically relevant concentrations 
of cilengitide in vitro, we observed inhibition of de novo 
adhesion to and detachment from vitronectin, well-known 
effects of cilengitide observed in a variety of cancer cell 
lines [8, 19, 31]. Cell-cell interactions between cancer 
cells and endothelium were also found to be crucial in 
the metastatic process. It was shown that αvβ3 integrin 
on melanoma cells interacts with Thy1 on endothelial 
cells in order to facilitate metastasis [32]. Therefore, in 
addition to the here reported inhibition of adhesion to 
the extracellular matrix by cilengitide, it is likely that the 
compound also inhibited the interaction of osteosarcoma 
cells with the vasculature and thereby further contributed 
to the in vivo observed suppression of metastasis. 
Different from findings in breast carcinoma and multiple 
myeloma [13, 33], in our osteosarcoma model cilengitide 
did not inhibit osteolysis, examined by micro-computed 
tomography (data not shown), implying that, under our 
treatment settings, bone resorption by osteoclasts was not 
suppressed. The modest anti-tumor effect of cilengitide 
seen in vivo is in line with the in vitro the G1-cell cycle 
block, recognized for the first time in our study, and 
induction of anoikis resulting in a limited effect on 
viability. In melanoma, meningioma and breast carcinoma 
animal models, much like in our model, cilengitide, 
used as a single drug, did not affect tumor growth, but a 
synergistic effect was observed when cilengitide treatment 
was combined with chemotherapy or radiotherapy [30, 
34, 35]. Thus, such a combination therapy needs to be 
envisaged in future osteosarcoma treatment studies.
In order to investigate alterations in cell signaling 
upon inhibition of integrins we focused on the Hippo 
signaling pathway, an evolutionarily conserved tumor 
suppressor pathway [36]. Activation of the Hippo 
pathway leads to degradation of the YAP protein, thereby 
inhibiting its growth promoting function. Dysregulation 
of this pathway contributes to various aspects of cancer 
progression, including metastasis. Hippo pathway 
inactivation has been observed in a variety of human 
cancers [37]. Abundant expression of YAP has also been 
found in osteosarcoma [38]. In the recent years, the 
Hippo pathway received substantial attention and key 
components and several negative and positive regulators 
have been characterized [39]. However, cell surface-
located regulatory components of the Hippo pathway 
are largely unknown. Here, the αvβ3 and αvβ5 integrins 
were for the first time identified as negative regulators 
of the Hippo pathway in osteosarcoma cells. This was 
reflected by the suppression of YAP target genes including 
the CYR61 gene upon integrin inhibition. Interestingly, 
CYR61, found downregulated in cilengitide-treated cells, 
has been recognized as a metastasis promoting protein 
in osteosarcoma [40]. Our data are in line with recent 
findings demonstrating that inhibition of integrin-linked 
kinase activity in breast, prostate and colon cancer cells 
activated the Hippo pathway [41].
Unfortunately, cilengitide failed to improve the 
survival of glioblastoma patients in a Phase III trial, and 
its development as an anti-cancer drug was subsequently 
cancelled [15]. Nevertheless, an integrin-targeting 
therapeutic strategy remains an attractive option in cancer 
management.
In conclusion, αvβ3 and αvβ5 integrin targeting, 
reactivating the Hippo signaling pathway, has potential 
as a strategy for metastasis suppressive treatment in 
osteosarcoma and presumably in other malignancies and 
should be further explored in clinical settings.
MATERIALS AND METHODS
Human osteosarcoma tissue microarray analysis
Osteosarcoma tissue specimens, including biopsies 
and primary tumor, relapse and metastases surgical 
resections, were collected between June 1990 and 
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December 2005 from 86 patients in accordance with the 
regulations of the local ethic committee. Clinical data of 
the patients are presented in Supplementary Table S2. 
A tissue microarray was constructed as described [42]. 
The immunostaining for αvβ3 and αvβ5 integrins was 
performed with anti- αvβ3 (clone EM22703) and anti-
αvβ5 (clone EM09902) rabbit monoclonal antibodies 
kindly provided by Simon L. Goodman as recently 
reported [26]. The immunohistochemical evaluation of 
αvβ3 integrin expression was carried out individually 
for tumor and stromal cells and the absence (negative) or 
presence (positive) of immunoreactive staining was judged 
by eye. Grading of αvβ5 integrin immunohistochemical 
staining, based on the intensity and the percentage of 
immunostained area, was done with a custom made 
MATLAB (v2009b, Mathworks Inc) program as described 
[43].
Cell culture and reagents
The human osteosarcoma cell lines 143-B (CRL-
8303), U2OS (HTB-96) and SaOS-2 (HTB-85) were 
obtained from American Type Culture Collection 
(ATCC). Cells were stably transduced with a LacZ gene, 
selected as described [43–45], and cultured in DMEM 
(4.5 g/l glucose)/HamF12 (1:1) medium (Invitrogen) 
supplemented with 10% heat inactivated fetal bovine 
serum (FBS, Gibco) (referred to as tissue culture 
medium) at 37°C in a humidified atmosphere of 5% 
CO2 and 95% air. The cell lines were authenticated by 
short tandem repeat DNA profiling (Microsynth) with a 
PowerPlex®16HS system (Promega) and by comparison 
with the German Collection of Microorganisms and Cell 
Cultures database (DSMZ). Cilengitide (EMD121974) 
was provided by Merck KgaA. Cisplatin was purchased 
from Sigma-Aldrich. Z-VAD-FMK (referred to in the text 
as Z-VAD) was purchased from BD Pharmingen (550377).
Analysis of integrin expression in osteosarcoma 
cell lines
Cells were detached in a buffer for flow cytometry 
(1 × PBS; 4 mM EDTA; 2% FBS) and incubated on 
ice with antibodies to αvβ3 (clone LM609, MAB1976, 
Millipore, dilution 1:200) and αvβ5 (clone P1F6, 
MAB1961, Millipore, dilution 1:200) integrins for 30 
minutes. After washing twice with the buffer described 
above, the cells were further incubated on ice in the dark 
with a fluorescently-conjugated secondary antibody (IgG-
PE, Novus Biologicals, 20103, dilution 1:200) for 20 
minutes. Non-bound secondary antibodies were removed 
by additional washing steps. Control cells were not stained 
or incubated with the secondary antibody alone. The mean 
fluorescence intensity of the fluorescently-labeled cells 
was then analyzed on a FACS machine (Calibur, BD) and 
with FlowJo software (Tree Star).
Adhesion assay
Adhesion assays were carried out in 96-well plates. 
The wells were coated with 200 ng/cm2 of vitronectin 
(Sigma-Aldrich, SRP3186) diluted in PBS supplemented 
with 0.1% BSA for 1 hour at room temperature (RT). 
After washing with PBS, the wells were blocked with 
heat-denatured (HD) 1% BSA in PBS for 1 hour at RT. 
Wells coated with HD-BSA alone were used as controls. 
In the de novo adhesion assay, cells were detached with 
accutase (Sigma-Aldrich, A6964), resuspended in DMEM/
F12/0.1% BSA and 5 × 103 cells in 50 μl were seeded 
in triplicates into wells containing 50 μl of increasing 
concentrations of cilengitide and allowed to adhere for 15 
minutes at 37°C. In the detachment assay, 2 × 103 cells/
well were seeded in triplicates in 80 μl of tissue culture 
medium into vitronectin-coated wells and left to fully 
adhere overnight. The next day, 20 μl of cilengitide at 
increasing concentrations were added to the wells and 
incubated for 2 hours at 37°C. Non-adherent cells were 
removed by washing with PBS and adherent cells were 
fixed with 10% formalin in PBS for 15 minutes at RT and 
then stained with 0.05% crystal violet in H2O or DAPI 
(1:1000) for 15 minutes at RT in the de novo adhesion 
assay and the detachment assay, respectively. Images of 
randomly selected areas of 3.6 mm2 were taken with an 
AxioCam MRm camera connected to the Zeiss Observer.
Z1 inverted microscope (Carl Zeiss MicroImaging GmbH) 
set at 4x magnification. The number of adherent cells in 
the analyzed area was determined with ImageJ software 
(http://rsb.info.nih.gov/ij/) and the total number of 
adherent cells per well was then calculated. The number 
of adherent cells treated with cilengitide was normalized 
to the number of adherent untreated cells set to 100%. The 
data of three independent experiments are presented.
Migration assay
The migratory properties of osteosarcoma cells 
were assessed in a wound healing migration assay. Cells 
were seeded into 6-well plates. At confluency, six wounds 
per well measuring between 0.3 and 1 mm in width and 
approximately 1 cm in length were applied with a sterile 
pin. Cell debris was removed by washing twice with tissue 
culture medium. Tissue culture medium with or without 
indicated concentrations of cilengitide was then added to 
the wells and 143-B or U2OS cells were incubated for 7 or 
24 hours, respectively. Wounds were marked with a Nikon 
object marker attached to a Nikon Diaphot microscope. 
Photos of the marked wounds were taken with an 
AxioCam MRm camera connected to the Zeiss Observer.
Z1 inverted microscope (Carl Zeiss MicroImaging GmbH) 
set at 4x magnification immediately after wounding and 
after the incubation with cilengitide. The width of the 
marked wound areas were measured with the ImageJ 
software (http://rsb.info.nih.gov/ij/). The migration rate 
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(μm/h) was calculated according to the formula (D0-Dt)/2t, 
where D0 is the wound width immediately after wounding 
and Dt is the wound width after the incubation for the 
indicated time (t). The migration rate of untreated cells 
was set to 100%. The experiments were done in duplicates 
and repeated at least three times.
Cell viability assay
Cell viability assays were performed in 96-well 
plates. 2 × 103 143-B or 5 × 103 U2OS or SaOS-2 cells per 
well were seeded in tissue culture medium and allowed to 
adhere overnight. Increasing concentrations of cilengitide 
were added the next day and the cells were incubated for 
6 or 24 hours. Following cilengitide treatment, the cells 
were incubated with 10 μl/well of WST-1 reagent (Roche, 
05015944001) for 3 hours and the cell viability was then 
assessed as previously described [46]. Three independent 
experiments in triplicates were performed.
Cell cycle analysis
Cell cycle progression was measured by 
propidium iodide (PI) staining using flow cytometry. 
Briefly, tissue culture medium alone containing 
different concentrations of cilengitide were added to 
fully attached and spread cells at approximately 50% 
confluency and incubated for 24 hours (143B, U2OS) 
or 48 hours (SaOS-2) according to the doubling time 
of the respective cell lines. Following the treatment, 
adherent cells were trypsinized and collected together 
with the floating cells, washed once with cold PBS 
and resuspended in 300 μl of PBS. Subsequently, 
the cells were fixed in ice cold ethanol and stored at 
-20°C overnight. The next day, DNA was stained in 
PI/RNase staining buffer (BD Pharmingen, 550825) 
for 30 minutes at 37°C in the dark. The samples were 
analyzed on a FACS machine (Calibur, BD) and the cell 
cycle distribution in % was calculated using FlowJo 
software (Tree Star). The experiments were performed 
in triplicates and repeated three times.
Western blotting
The preparation of protein extracts and Western blot 
analysis were performed as previously described [43]. 
Antibodies used were anti-PARP (9542, dilution 1:1000) 
obtained from Cell Signaling Technology, anti-actin 
(MAB1501, dilution 1:10000) from Millipore, and anti-
GAPDH (FL-335, dilution 1:3000), anti-Cyr61 (sc271217, 
dilution 1:1000), anti-CyclinD1 (sc20044, dilution 1:1000) 
and HRP-conjugated secondary antibodies (sc2006, 
sc2055, dilution 1:5000) were purchased from Santa Cruz 
Biotechnologies. Peroxidase activity was visualized with 
Immobilon chemoluminescence substrate (Millipore, 
WBKLS0500) and a VersaDocTM Imaging System (Bio-
Rad).
RNA extraction, cDNA synthesis and 
quantitative real-time polymerase chain reaction 
(qPCR)
Total RNA from cells treated with various 
concentrations of cilengitide or left untreated was isolated 
with a RNeasy Mini Kit (Qiagen, 74104) according 
to the manufacturer’s instructions. 1 μg of total RNA 
was transcribed to cDNA with a High-Capacity cDNA 
Reverse Transcription Kit with Rnase Inhibitor (Applied 
Biosystems, 4374966) as described in the protocol 
provided by the manufacturer. The cDNA was diluted in 
nuclease-free water and real-time qPCR was conducted on 
cDNA equivalent to 10 ng of starting RNA with the Power 
SYBR Green PCR Master Mix (Applied Biosystems, 
4367659) on a StepOne-Plus Real-Time PCR System 
(Applied Biosystems). The denaturation was performed 
for 10 minutes at 95°C followed by 40 PCR cycles for 15 
seconds at 95°C and for 1 minute at 60°C. The analysis 
was done with StepOne Software version 2.1 (Applied 
Biosystems). Relative expression levels were calculated 
by the comparative (ΔΔCT) method and normalized to 
GAPDH. All primers used are listed in Supplementary 
Table S3. The experiments were done in triplicates and 
repeated three times.
Cilengitide treatment in an intratibial xenograft 
osteosarcoma model in SCID mice
The animal study was approved by the Ethics 
Committee of the Veterinary Office of the Canton Zurich 
and was conducted in accordance with the Swiss Animal 
Protection Law. In order to enable visualization of tumor 
cells within mouse tissues in vivo and ex vivo, 143-B/
LacZ cells were transduced with an mCherry gene (143-
B/mCherry/LacZ cells) as described recently [21]. Eight 
to ten week old SCID/CB17 immunocompromised 
mice purchased from Charles River Laboratories 
were intratibially injected with 10 μl of 105 143-B/
mCherry/LacZ cells in PBS/0.05% EDTA on day 0. 
Eight days after tumor cell injection (TCI), the mice 
were randomly distributed into two groups and daily 
intraperitoneal injections of 10 mg/kg body weight of 
cilengitide (treatment group) or vehicle (physiological 
saline) (control group) were initiated. The cilengitide-
treated group consisted of 11 mice, whereas the vehicle-
injected control group included 12 mice. Primary tumor 
development was examined weekly by X-ray with an 
MX-20 DC Digital Radiography System (Faxitron X-Ray 
Corporation) and by mCherry fluorescence imaging with 
an IVIS imaging system (Caliper Life Sciences, Inc.). 
The mCherry fluorescence was quantified with a Living 
Image software version 3.1 (Xenogen Corporation). 
Caliper measurements of the length and the width of 
the tumor leg were performed weekly and the primary 
tumor volume was calculated with the formula V=length 
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× width2/2. The volume of the non-injected leg was used 
as a reference value. The animals were sacrificed after 
20 days of treatment and the primary tumors and in situ 
perfused lungs were harvested as reported [45]. Organs 
were fixed for 30 minutes at RT in 2% formaldehyde 
and X-gal stained as described [47, 48]. Indigo-blue 
stained pulmonary metastases on the lung surface were 
counted at 4x magnification under the Nicon Eclipse E600 
microscope (Nikon Corporation).
Statistical analysis
Statistical significance of differences between the 
experimental groups was determined using a Student t test 
or ANOVA and P < 0.05 was considered significant. All 
analyses were performed using GraphPad Prism Version 
5.01 (GraphPad Software, Inc.). The same software was 
used to calculate the half-maximal adhesion inhibitory 
concentration (IC
50
) of cilengitide. The results are 
presented as means ± SEM.
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